Free Testosterone: Pumping up the Tires or Ending the Free Ride?
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The review by Goldman et al. (1) is a strong restatement of the free hormone hypothesis (FHH) with its contingent focus on measurement of so-called “free” testosterone (FT). The FHH has even been recently described as a “central dogma of endocrinology” (2), reminiscent of the hubris of Crick’s (3) central dogma of molecular biology stated as a unidirectional information transfer from DNA to RNA to protein, which proved neither a dogma (an unassailable proposition) nor universally correct. The review provides an outstandingly clear and encyclopedic summation of what is and is not known of the molecular mechanisms of testosterone binding to circulating binding proteins. On the other hand, its coverage of FT measurement and its interpretation are both more selective and tendentious. Above all the review’s overall focus on means rather than ends, on how to do it rather than why, the review belies why the application of FT measurements remain contentious so that less expert readers may wonder what controversy there is that the authors hint at fleetingly. Despite being extant for decades, the use of FT measurement has barely been stated in a testable form and virtually never directly tested as a refutable hypothesis. Rather by inference and repetition as if it is self-evident, it has become entrenched as an enthusiastically wielded yet largely untested concept that goes from one paper to the next without ever seeming to pass through a questioning mind. The FHH originated in a now obsolete 1970s pharmacology theory of adverse drug reactions by which such interaction was attributed to mutual displacement of drugs bound to circulating binding proteins (4). That now discarded speculative concept (5) has been superseded by physiological drug interaction mechanisms, such as molecular receptor binding, cytochrome P450 induction/inhibition, P-glycoprotein, and ion channel blockade (6). Contemporaneously, the 1970s provided fertile ground for introducing the concept of “free” hormones into Endocrinology. The revolutionary invention of radioimmunoassay introduced the notions of free and bound hormones in immunoassay and also hormone receptor theory, both deriving from the biochemical theory of equilibrium binding equations. Although pharmacological theories evolved, FHH persisted in Endocrinology making a remarkable transit from a simple, illustrative heuristic to quasi-axiomatic status without ever undergoing critical empirical testing. Regardless of its flimsy basis, invoking FT has flourished as a panchreston (explain-all), a final arbiter to resolve uncertainty about androgen status. This reached a farcical zenith in papers glorifying FT calculation as by the “Law of Mass Action,” an affectation comparable with describing measuring weight on a miscalibrated scale according to the “Law of Gravity.” In that sense the review is a welcome restatement of a hypothesis whose quasi-axiomatic status has granted it a free pass from engaging with logic or evidence in its application. To provide a more nuanced picture, an alternative view that FT represents a muddled and misleading concept, an explanatory fiction that provides false reassurance in men’s reproductive health care, is outlined briefly. The fatal flaw of FHH theory, not addressed in the review, is its lack of a coherent physiological basis for interpretation of FT. Although the review notes the evidence refuting each of the three key assumptions of interpreting FT—that only unbound testosterone is able to enter tissues to exert androgenic effects, that testosterone bound to circulating proteins constitutes an inert buffer, and that the same mechanisms operate equally in all tissue capillaries—it proceeds as if these defects do not matter. Most critically, the assertion that the small fraction of unbound (or loosely bound) circulating testosterone represents its most active moiety lacks sound logical basis. Even accepting the assertion that testosterone must transit through a “free” compartment on its way to tissues, that moiety would be just as accessible to sites of degradation, where it is metabolically inactivated. On that basis FT may equally reflect the most readily metabolized, least active and most evanescent, fraction of circulating testosterone rather than the most bioactive. Thus it cannot be known a priori whether FT measurement reflects androgen action, androgen degradation or some net balance between them. In this light it is inexplicable, a meme finding a receptive host, how one could arrive at the a priori generic interpretation that FT measurement represents the most active fraction of circulating testosterone for any or all tissues. Even accepting these assumptions as doctrinal verities, the focus on FT represents an excessively narrow, simplistic view of testosterone action that overlooks aromatization and amplification to testosterone’s potent bioactive metabolites, estradiol and dihydrotestosterone, respectively. In this light it is doubtful that m
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Central Dogma of Molecular Biology
CRICK, F. (1970) · Nature · doi:10.1038/227561a0 · Cited by 3,444
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Södergard, R., Bäckström, T., Shanbhag, V., & Carstensen, H. (1982) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(82)90038-3 · Cited by 1,080
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Impaired retinal function and vitamin A availability in mice lacking retinol‐binding protein
Quadro, L., Blaner, W. S., Salchow, D. J., Vogel, S., Piantedosi, R., Gouras, P., Freeman, S., Cosma, M. P., Colantuoni, V., & Gottesman, M. E. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4633 · Cited by 506
Bhasin, S., Pencina, M., Jasuja, G. K., Travison, T. G., Coviello, A., Orwoll, E., Wang, P. Y., Nielson, C., Wu, F., Tajar, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-3012 · Cited by 355
Travison, T. G., Vesper, H. W., Orwoll, E., Wu, F., Kaufman, J. M., Wang, Y., Lapauw, B., Fiers, T., Matsumoto, A. M., & Bhasin, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2935 · Cited by 326
Coolens, J.-L., Van Baelen, H., & Heyns, W. (1987) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(87)90071-9 · Cited by 290
Cited by
Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism
Jayasena, C. N., Anderson, R. A., Llahana, S., Barth, J. H., MacKenzie, F., Wilkes, S., Smith, N., Sooriakumaran, P., Minhas, S., Wu, F. C. W., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14633 · Cited by 147
Narinx, N., David, K., Walravens, J., Vermeersch, P., Claessens, F., Fiers, T., Lapauw, B., Antonio, L., & Vanderschueren, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04562-1 · Cited by 96
Skiba, M. A., Bell, R. J., Herbert, D., Garcia, A. M., Islam, R. M., & Davis, S. R. (2021) · Human Reproduction · doi:10.1093/humrep/deab069 · Cited by 22
Venkatesh, V. S., Grossmann, M., Zajac, J. D., & Davey, R. A. (2022) · Obesity Reviews · doi:10.1111/obr.13429 · Cited by 22
Martínez-Escribano, A., Maroto-García, J., Ruiz-Galdón, M., Barrios-Rodríguez, R., Álvarez-Millán, J. J., Cabezas-Sánchez, P., Plaza-Andrades, I., Molina-Vega, M., Tinahones, F. J., Queipo-Ortuño, M. I., et al. (2020) · Biomolecules · doi:10.3390/biom10121697 · Cited by 11
Metadata
- Authors
- Handelsman, D. J.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2017-08-01
- Volume
- 38
- Issue
- 4
- Pages
- 297-301
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2742787498
- Cited by
- 78
- References
- 22
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Free Testosterone: Pumping up the Tires or Ending the Free Ride? https://app.cochat.ai/papers/10.1210/er.2017-00171
- The paper
- Handelsman, D. J. (2017). Free Testosterone: Pumping up the Tires or Ending the Free Ride? Endocrine Reviews. https://doi.org/10.1210/er.2017-00171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.